Please login to the form below

Not currently logged in

Pharma companies announce new appointments

Robert Hoffman rejoins Arena Pharmaceuticals, Frank J Wright joins Marken, Mark Suto joins Southern Research and William M Harrison joins the board of Numira Biosciences
Several pharma company appointments have been announced in recent days. Robert E Hoffman has rejoined Arena Pharmaceuticals in his former role of vice president, finance and chief financial officer.

Hoffman had left Arena in March this year, after having been with the company for 13 years. He first served as Arena's vice president, finance and chief financial officer from December 2005 to March 2011; he also previously held the roles of chief accounting officer and controller. In his time away from Arena, he was chief financial officer for Polaris Group, a private biopharmaceutical company.

Marken appoints Frank Wright
Marken, a clinical supply chain services provider, has appointed Frank J Wright as interim president of the clinical trials distribution business unit.

Wright, who co-founded drug development company Aptuit in 2004, where most recently he held the position of vice chairman of external value creation and global integration activities, joins Marken with over 40 years' industry experience. He has worked for ICI, Glaxo and ChiRex, and currently holds several senior advisory positions. In his new role at Marken, Wright will be responsible for growing the business, enhancing the team and detecting potential investment opportunities, as well as identifying a permanent president of the business unit.

Mark Suto joins Southern Research Institute
The Southern Research Institute in Alabama, US, has appointed Mark J Suto, PhD to the role of vice president of its drug delivery division.

Dr Suto's career began at Parke-Davis Pharmaceutical Research in 1982, and has since included roles at DuPont Pharmaceuticals, Signal Pharmaceuticals, Deltagen Research Laboratories, CombiChem and Neurion Pharmaceuticals, culminating in his most recent position as vice president of chemical and pharmaceutical sciences at Icagen, a role he held since 2004. In his new role, Dr Suto, a member of the American Chemical Society, will focus on basic research and target identification, and lead discovery and optimisation of new therapies for cancer, infectious diseases and neurological diseases and disorders.

VIDA Sciences appoints William Harrison
Finally, William M Harrison, chief executive officer of contract research organisation (CRO) consultancy VIDA Sciences, has been appointed to the board of directors of Numira Biosciences, a speciality CRO. Harrison has spent 25 years in various senior management roles (including president and chief operating officer) at MPI Research, a CRO.

15th August 2011


COVID-19 Updates and Daily News

Featured jobs


Add my company

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...